Health Care

Discover why AstraZeneca’s ovarian‑cancer phase‑three study and strategic market‑access plan could boost its $26 billion revenue forecast and 12 % IRR—read the latest analyst insights and M&A prospects.

Abbott Laboratories’ rise as a key ETF holding fuels $2.3 billion of inflows, 18.4 % 12‑month return, strong cash flow, and AI‑driven growth, positioning it to boost value and patient care.

Sanofi’s December 2025 NMPA approvals for Qfitlia and Cablivi, plus the ViceBio ADC acquisition, position the company to dominate China’s rare‑disease market, yet reimbursement shifts and integration risks could impact long‑term gains.

Siemens Healthineers launches new oncology, defence and AI initiatives while shares dip 1.5 %, yet its robust margins and R&D focus promise long‑term growth in a shifting reimbursement landscape.

Merck’s RSV antibody pipeline shows 68% risk reduction in high‑risk infants, but FDA safety reviews may delay launch—investors weigh clinical promise against regulatory risk.

Sonova Holding AG shares dip in a muted Swiss market, yet valuation metrics stay steady, showing no core distress amid central‑bank watch.

Agilent Technologies’ growth in cell‑therapy analytics and genomic sequencing—backed by high‑margin consumables, AI‑driven software, and value‑based reimbursement—outpaces the life‑sciences sector, fueling investor confidence.

Veeva Systems’ cloud‑based CRM for life‑sciences shows stable growth and strong fundamentals—market swings reflect sentiment, not operational change.

Explore Baxter International’s breakthrough smart‑pump study with 64% fewer medication errors, its impact on staff workload, and the latest class‑action lawsuit updates for investors and clinicians.

Discover how Astellas Pharma’s precision‑medicine pipeline—targeting ovarian cancer, chordoma, GI oncology and more—drives global growth, market expansion and innovative partnerships.